Recurrent Small Cell Lung Cancer (SCLC) Completed Phase 2 Trials for Nintedanib (DB09079)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01441297BIBF 1120 as Second Line Treatment for Small Cell Lung CancerTreatment